Retrospective study on clinical efficacy of Evolocumab in highrisk ASCVD patients
Pharm. pract. (Granada, Internet)
; 21(2): 1-7, abr.-jun. 2023. tab, graf
Article
em En
| IBECS
| ID: ibc-222793
Biblioteca responsável:
ES1.1
Localização: ES15.1 - BNCS
ABSTRACT
Objective: This study evaluated the effectiveness of Evolocumab by measuring achievement target LDL-C among high-risk ASCVD patients in the UAE. Method: A retrospective observational study included 27 patients with high-risk ASCVD receiving Evolocumab 140 mg/mL SC injection every 2 weeks. The effectiveness of Evolocumab is measured by the mean reduction in LDL-C levels from baseline and achieving target LDL levels according to ECS/EAS guideline during average follow up period. Results: The average (SD) age of the patients is 52 (10) years. Majority of the patients were male (n=22), smokers (40.9%), overweight or obese (78%), had a history of hypertension (59.3%), MI (55.5%) and diabetes (40.7%). The patients were on Evolucomab therapy due to persistently elevated LDL-C (n=25) or statin intolerance (n=2). During the average follow up period of 42 weeks,14 patients (51%) achieved target LDL-C level. During this period, LDL-C and TC levels reduced from 3.51(1.3) mmol/L to 1.9 (1.2) mmol/L and from 4.97 (1.4) mmol/L to 1.62 (1.09) mmol/L, respectively post Evolocumab therapy. Conclusion: The reduction was statistically significant. However, the reduction of TG levels and the increase in HDL level was not significant. Evolocumab reduces LDL-C and TC levels significantly in high-risk ASCVD patients in a tertiary hospital in the UAE population. (AU)
Palavras-chave
Texto completo:
1
Coleções:
06-national
/
ES
Base de dados:
IBECS
Assunto principal:
Doenças Cardiovasculares
/
Resultado do Tratamento
Limite:
Adult
/
Aged
/
Female
/
Humans
/
Male
País/Região como assunto:
Asia
Idioma:
En
Revista:
Pharm. pract. (Granada, Internet)
Ano de publicação:
2023
Tipo de documento:
Article